Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 1Dermatologic 1

Conditions

Carcinoma, Squamous Cell 1Carcinoma, Basal Cell 1

Interventions

Cyclophosphamide 548pembrolizumab 386Radiotherapy 363Bevacizumab 360Carboplatin 351Rituximab 316Cisplatin 300Gemcitabine 297Paclitaxel 288Dexamethasone 273Docetaxel 271fludarabine phosphate 241Doxorubicin 231Nivolumab 220Etoposide 209Cytarabine 203Lenalidomide 201fludarabine 191Oxaliplatin 191Fluorouracil 190Melphalan 189Filgrastim 188Capecitabine 175Calcium Dobesilate 173Radiosurgery 167Erlotinib Hydrochloride 167Methotrexate 163Bortezomib 162Granulocyte Colony-Stimulating Factor 154Whole-Body Irradiation 144

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Has results × remetinostat × Clear all
NCT03180528 2021-06-08

Topical Remetinostat in Treating Patient With Cutaneous Basal Cell Cancer

Stanford University

Phase 2 Completed
30 enrolled 10 charts
Dermatologic

Carcinoma, Basal Cell

NCT03875859 2021-05-20

Topical Remetinostat Gel as Neoadjuvant Therapy in Patients With Squamous Cell Carcinoma (SCC)

Stanford University

Phase 2 Terminated
4 enrolled 9 charts
Tumor-Agnostic

Carcinoma, Squamous Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡